Abstract:Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, Beijing 100191, People’s Republic of China Purpose: B7 homologue 6 (B7-H6) has been found at an up-regulated level in multiple cancer cells and identified to be positively correlated with inferior clinical features. In non-Hodgkin lymphoma (NHL), however, the roles of B7-H6 and the underlying mechanism of action remain unclear. Through in vivo and in vitro experiments, the aim of this study was to explore the regulatory mechanism of B7-H6 in NHL in order to provide new therapeutic strategies that can potentially be applied in clinical practice. Methods: The expression of B7-H6 in T-lymphoblastic lymphoma (TLBL), diffuse large B cell lymphoma (DLBCL) and lymph node reactive hyperplasia (LRH) tissues were compared by immunohistochemistry. A total of 10 NHL cell lines were screened by Western blot to evaluate the expression of B7-H6. The effects of B7-H6 knockdown on cell proliferation, migration and invasion of NHL cells were studied in vivo using a transplanted tumor mice model, and in vitro by Cell Counting Kit-8 (CCK-8) and Transwell assays. Quantitative phosphoproteomics was performed to identify the changes of protein phosphorylation and related pathways affected by B7-H6. The effects of B7-H6 on NHL were validated via B7-H6 overexpression and pathway inhibitor assays. Results: The expression levels of B7-H6 in NHL cell lines, and TLBL and DLBCL tissues were significantly increased compared with those in the control groups. Inhibition of cell proliferation, migration and invasion was observed in Jurkat and Raji cells with B7-H6 knockdown. The ability of B7-H6 in promoting tumorigenesis was further validated by in vivo experiments. In addition, Ras and HIF-1 signaling pathways were shown to be significantly affected by B7-H6 through quantitative phosphorylation proteomics analysis. Ras/MEK/ERK pathway was verified to be significantly inhibited after B7-H6 knockdown byWestern blot analysis. Strikingly, MEK inhibitor AZD8330 was found to have the ability to sufficiently inhibit Ras/MEK/ERK pathway, partially reverse cell proliferation and completely reverse cell migration and invasion induced by B7-H6. Conclusion: B7-H6 promotes cell proliferation, migration and invasion in NHL via Ras/ MEK/ERK pathway. Hence, B7-H6 or Ras/MEK/ERK pathway targeting may be used as potential therapeutics for treating NHL.

Progress of B7-H6 molecule in malignant tumors

High expression of B7-H6 in human glioma tissues promotes tumor progression

Knockdown of B7-H6 Inhibits Tumor Progression and Enhances Chemosensitivity in B-Cell Non-Hodgkin Lymphoma

B7-H6 Expression Correlates with Cancer Progression and Patient's Survival in Human Ovarian Cancer.

B7-H4 expression in various tumors determined using a novel developed monoclonal antibody

Expression of B7-H6 Expression in Human Hepatocellular Carcinoma and Its Clinical Significance

Ott_a_257512 5795..5805

Expression, Pathways, and Therapeutic Strategies

B7 Homolog 6 Promotes the Progression of Cervical Cancer

The Role of B7-H3 in Tumors and Its Potential in Clinical Application.

[Research Advances of A New Co-stimulatory Molecule-B7 Homolog 6--Review].

Knockdown of B7H6 Inhibits Tumor Progression in Triple-Negative Breast Cancer.

B7-H6 expression in non-small cell lung cancers.

B 7-H 6 expression correlates with cancer progression and patient ’ s survival in human ovarian cancer

Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer.

B7-H6 is a New Potential Biomarker and Therapeutic Target of T-lymphoblastic Lymphoma

B7-H4 enhances oncogenicity and inhibits apoptosis in pancreatic cancer cells

B7-H6 Promotes Cell Proliferation, Migration and Invasion of Non-Hodgkin Lymphoma via Ras/MEK/ERK Pathway Based on Quantitative Phosphoproteomics Data.

B7-H6 is Associated with Poor Prognosis and a Potential Therapeutic Target of T-Lymphoblastic Lymphoma

B7-H4’s Role “Beyond the Tumor”

Functional Expression of B7H1 on Pancreatic Carcinoma Panc-1 Cells